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 Comment 
the infarction since complement activation is known to be asso-
ciated with both atherosclerosis and ischemia-reperfusion in-
jury  [8] .
 LVD patients with high C3 levels at 3 months were at risk for 
an unfavorable outcome. The association seen in the cryptogenic 
stroke patients for C3a with outcome was lost in a multivariate 
regression model.
 As addressed by the authors themselves, there are limitations 
to this study: as the data for the LVD and cryptogenic stroke pa-
tients were determined more than a year apart, a direct compari-
son of both groups is not possible. Also data on preceding infec-
tions and secondary infections as well as infarction volume were 
not available. All of those factors may alter C3 and C3a levels in 
peripheral blood. More robust data will be needed to test whether 
C3 or C3a levels or other members of the complement system re-
flect stroke severity and can indeed serve as an independent pre-
dictor for clinical outcome.
 The merit of the study by Stokowska et al.  [7] comes from the 
important observation that distinct stroke etiologies may also re-
sult in distinct activation patterns of the complement system. As 
complement is closely involved in the activation of the immune 
system, these differences may result in distinct activation patterns 
of the immune system depending on the stroke etiology. If con-
firmed, studies aiming to decipher the immune response in stroke 
should not only stratify their patient cohorts according to stroke 
severity but may need to control for stroke etiology and comple-
ment activation, too.
 
 The efforts to unravel the secondary consequences of acute 
stroke have led to investigations of the immunological altera-
tions induced by stroke. By now, multiple components of the im-
mune system have been identified that contribute to brain lesion 
development and/or affect the clinical outcome of stroke pa-
tients.
 Peripheral immune suppression, mainly affecting lympho-
cytes and monocyte function, has been shown to be an important 
predictor of bacterial infections, especially pneumonia  [1, 2] . 
Most authors agree that the occurrence of pneumonia will affect 
the clinical outcome of patients  [3] .
 In addition, an inflammatory infiltrate develops at the site of 
the stroke lesion. This immune response in the brain itself has 
dual consequences: on the one hand, proinflammatory cascades 
with the release of proinflammatory cytokines mediate neurotox-
icity, thus increasing infarction volume ; on the other hand, regu-
latory (T) cells dampen the immune response and inhibit brain 
injury  [4, 5] .
 Complement is involved in several aspects of the pathogenesis 
of stroke: complement factor C3 is synthesized in the liver as an 
acute phase protein and therefore increased in many inflammatory 
conditions. Its activated cleavage product C3a acts as proinflam-
matory mediator. C3 deposits have been found in atherosclerotic 
plaques. In addition, both C3 and C3a have been implicated in isch-
emia-reperfusion injury  [6] . As recently reviewed by Yanamadala 
and Friedlander  [6] , there is also evidence to support neuroprotec-
tive features of C3a in stroke and other types of brain injury.
 The majority of studies in human stroke have stratified pa-
tients according to stroke severity but not stroke etiology. In this 
issue of  Cerebrovascular Diseases, Stokowska et al.  [7] report dif-
ferences in complement activation in large-vessel disease (LVD) 
stroke and cryptogenic stroke.
 They investigated serum C3 and C3a complement levels in 
stroke due to LVD and cryptogenic stroke using samples from the 
Sahlgrenska Academy Study on Ischemic Stroke in the acute 
phase of ischemic stroke and 3 months later. These data were then 
correlated with clinical outcome at 3 months and 2 years.
 The authors found a persisting increase in C3 in both subtypes 
of stroke. C3a, though, normalized in cryptogenic stroke patients 
but remained elevated in LVD compared to controls at 3 months. 
These data could relate to the underlying pathology or the size of 
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